公开(公告)号：US11666557B2

公开(公告)日：2023-06-06

申请号：US16722773

申请日：2019-12-20

Applicant: Tempest Therapeutics, Inc.

Inventor： Nicholas Simon Stock ,  Austin Chih-Yu Chen ,  Yalda Mostofi Bravo ,  Jason Duarte Jacintho ,  Jill Melissa Baccei ,  Brian Andrew Stearns ,  Ryan Christopher Clark

IPC: A61K31/4196 ,  A61K31/41 ,  A61K31/4439 ,  A61K31/506 ,  C07D401/10 ,  C07D401/06 ,  C07D403/10 ,  C07D403/06 ,  C07D249/12 ,  A61P35/00 ,  A61P35/02

CPC classification number: A61K31/4196 ,  A61K31/41 ,  A61K31/4439 ,  A61K31/506 ,  A61P35/00 ,  A61P35/02 ,  C07D249/12 ,  C07D401/06 ,  C07D401/10 ,  C07D403/06 ,  C07D403/10

Abstract: The invention disclosed herein is directed to compounds of Formula I




and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.

公开(公告)号：US10568871B2

公开(公告)日：2020-02-25

申请号：US15590766

申请日：2017-05-09

Applicant: Tempest Therapeutics, Inc.

Inventor： Nicholas Simon Stock ,  Austin Chih-Yu Chen ,  Yalda Mostofi Bravo ,  Jason Duarte Jacintho ,  Jill Melissa Baccei ,  Brian Andrew Stearns ,  Ryan Christopher Clark

IPC: A61K31/4196 ,  C07D401/10 ,  C07D403/10 ,  C07D401/06 ,  C07D249/12 ,  C07D403/06 ,  A61K31/4439 ,  A61K31/506

Abstract: The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.

公开(公告)号：US09862708B2

公开(公告)日：2018-01-09

申请号：US15118402

申请日：2015-02-09

Applicant: Tempest Therapeutics, Inc.

Inventor： Nicholas Simon Stock ,  Austin Chih-Yu Chen ,  Yalda Mostofi Bravo ,  Jason Duarte Jacintho ,  Yen Truong

IPC: C07D231/20 ,  C07D231/54 ,  C07D401/10 ,  C07D401/12 ,  C07D405/10

CPC classification number: C07D405/10 ,  C07D231/20 ,  C07D231/54 ,  C07D401/10 ,  C07D401/12

Abstract: The invention disclosed herein is directed to compounds of Formula I [Formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers through the administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.